New York Rexulti Attorneys

Rexulti Lawsuits

In July 2015, Otsuka Pharmaceuticals received FDA approval for their new drug, Rexulti, an antipsychotic similar to Abilify. Abilify was previously found to cause extreme compulsive behaviors in users. The FDA approved Rexulti based on two clinical trials that evaluated the efficacy of the drug in Schizophrenic participants, as well as participants with Major Depressive Disorder. Both trials demonstrated fewer symptoms in Rexulti users than Abilify users. As a second-generation version of Abilify, Rexulti was meant to improve the clinical profile of the drug by causing fewer side effects. However, Rexulti had only a slight chemical distinction from Abilify, and shares a very similar chemical structure.

Serving Clients Nationwide

Rexulti Causing Compulsive Behaviors

One of the major side effects of Abilify is extreme compulsive behaviors, like gambling. Although a gambling warning was stated in the Rexulti product monograph, it was not listed in the medication guide for patients, or on the official website. This concealment of undesirable warnings or information from the public resulted in a number of reports of gambling by users of Rexulti. Due to the failure to warn, users were unaware of this possible side effect.

Expected complications associated with Rexulti include weight gain, sense of restlessness, and an increase in suicidal thought and behaviors among children and teens. Unexpected complications, such as impulse-control disorders, have also resulted from the use of this new drug. Like Abilify users, Rexulti users were reported experiencing compulsive behaviors, including pathological gambling and hyper-sexuality. The compulsive behaviors were prominent in users especially when the drug is taken with other antipsychotics with partial agonist activity at the dopamine receptors. Rexulti users with a history of impulse control disorders are at an even greater risk of experiencing these behaviors.

Researchers have found evidence suggesting excessive amounts of the neurotransmitters, dopamine and serotonin, trigger excessive compulsions leading to pathological gambling, hyper-sexuality, over-shopping, and even binge eating. These behaviors can have devastating emotional and financial consequences as users will do almost anything to continue their compulsive activity.

Have You Been Injured as a Result of Rexulti Use?

Rheingold Giuffra Ruffo & Plotkin LLP is currently investigating claims on behalf of injured users, as our firm has over 30 years of experience handling dangerous drugs cases. If you or someone you know has suffered from compulsive gambling, hyper-sexuality or other compulsive behaviors due to taking Rexulti, our New York defective drug attorneys at Rheingold Giuffra Ruffo & Plotkin LLP can help you fight to protect your rights. We take pride in helping people from across the nation with their most critical legal problems. Our New York dangerous drug attorneys provide clients with personal attention and guidance as they navigate through this stressful time.

Schedule an initial and free consultation with a member of our firm. Call (888)260-0473 today.

Verdicts & Settlements

  • Auto Accident $2,750,000
  • Biopsy Resulting In Blindness $2,500,000
  • Birth Injury $1,000,000
  • Brain Damage $12,000,000
  • Brain Damage of Infant $1,000,000
  • Brain Damage of Infant $2,100,000
  • Cancer Misdiagnosis $2,500,000
  • Cardiovascular Injury $2,200,000
  • Cataract Surgery Complication $1,700,000
  • Child's Hand Injury $9,000,000

What Sets Us Apart

  • Over 2 Billion Recovered

    We fight tirelessly to deliver results and we are not afraid to go to trial.

  • Recognized Leaders

    We are leaders and educators in legal issues involving personal injury, medical malpractice, and product liability.

  • 50+ Years of Experience

    We have the experience to handle your case all while providing individualized attention.

Request Your Free Consultation Today

Fill Out the Form Below to Get Started or Call Us At (888) 260-0473.

  • Please enter your first name.
  • Please enter your last name.
  • Please enter your phone number.
    This isn't a valid phone number.
  • Please enter your email address.
    This isn't a valid email address.
  • Please make a selection.
  • Please enter a message.